Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure

International Journal of Molecular Medicine

Volumn 17, Issue 2, 2006, Pages 369-375

  Pacher, Pál ^a,b   Liaudet, Lucas ^b,c   Mabley, Jon G ^b,d   Cziráki, Attila ^e   Haskó, György ^f,g   Szabó, Csaba ^b,f,h  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b INOTEK CORPORATION   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF BRIGHTON   (United Kingdom)

^e UNIVERSITY OF PÉCS   (Hungary)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^h SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Cardiac function; Doxorubicin; Endotoxin; Heart failure; Ischemia; Oxidative stress; Peroxynitrite; Tumor

Indexed keywords

DOXORUBICIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HEART DISEASE; MALE; METABOLISM; MOUSE; SURVIVAL RATE;

ANIMALS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOXORUBICIN; ENZYME INHIBITORS; HEART DISEASES; INDOLES; MALE; MICE; MICE, INBRED BALB C; POLY(ADP-RIBOSE) POLYMERASES; SURVIVAL RATE;

EID: 33644861815     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.2.369     Document Type: Article

References (28)

1. Pacher P, Schulz R, Liaudet L and Szabo C: Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26: 302-310, 2005.
2. Ungvari Z, Gupte SA, Recchia FA, Batkai S and Pacher P: Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3: 221-229, 2005.
3. Pacher P, Vaslin A, Benko R, Mabley JG, Liaudet L, Hasko G, Marton A, Batkai S, Kollai M and Szabo C: A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J Pharmacol Exp Ther 311: 485-491, 2004.
4. Xiao CY, Chen M, Zsengeller Z, Li H, Kiss L, Kollai M and Szabo C: Poly(ADP-ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther 312: 891-898, 2005.
5. Pacher P, Liaudet L, Mabley J, Komjati K and Szabo C: Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 40: 1006-1016, 2002.
6. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT and Szabo C: Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107: 896-904, 2003.
7. Batkai S, Pacher P, Jarai Z, Wagner JA and Kunos G: Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol 287: H595-H600, 2004.
8. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C and Curello S: Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 10: 1699-1711, 2004. (Pubitemid 38559780)
9. Jagtap P and Szabo C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421-440, 2005.
10. Pacher P, Cziraki A, Mabley JG, Liaudet L, Papp L and Szabo C: Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents. Biochem Pharmacol 64: 1785-1791, 2002.
11. Szenczi O, Kemecsei P, Holthuijsen MF, van Riel NA, van der Vusse GJ, Pacher P, Szabo C, Kollai M, Ligeti L and Ivanics T: Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol 69: 725-732, 2005.
12. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G and Szabo C: Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300: 862-867, 2002. (Pubitemid 34164989)
13. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E and Szabo C: The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51: 514-521, 2002.
14. Pillai JB, Russell HM, Raman J, Jeevanandam V and Gupta MP: Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol 288: H486-H496, 2005.
15. Xiao CY, Chen M, Zsengeller Z and Szabo C: Poly(ADPribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. J Pharmacol Exp Ther 310: 498-504, 2004.
16. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, Schmalstieg FC, Komjati K, Mabley JG, Szabo C, Salzman AL and Traber DL: Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am J Physiol 285: L240-L249, 2003.
17. Khan TA, Ruel M, Bianchi C, Voisine P, Komjati K, Szabo C and Sellke FW: Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. J Am Coll Surg 197: 270-277, 2003.
18. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C and Brownlee M: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112: 1049-1057, 2003.
19. Komjati K, Mabley JG, Virag L, Southan GJ, Salzman AL and Szabo C: Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int J Mol Med 13: 373-382, 2004.
20. Murakami K, Enkhbaatar P, Shimoda K, Cox RA, Burke AS, Hawkins HK, Traber LD, Schmalstieg FC, Salzman AL, Mabley JG, Komjati K, Pacher P, Zsengeller Z, Szabo C and Traber DL: Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock 21: 126-133, 2004.
21. Murthy KG, Xiao CY, Mabley JG, Chen M and Szabo C: Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction. Shock 21: 230-234, 2004.
22. Farivar AS, Woolley SM, Fraga CH, Thomas R, Salzman AL, Szabo C and Mulligan MS: Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury. Ann Thorac Surg 77: 1938-1943, 2004.
23. Szabo G, Soos P, Mandera S, Heger U, Flechtenmacher C, Seres L, Zsengeller Z, Sack FU, Szabo C and Hagl S: Mesenteric injury after cardiopulmonary bypass: role of poly(adenosine 5′- diphosphate-ribose) polymerase. Crit Care Med 32: 2392-2397, 2004. (Pubitemid 39648218)
24. Szabo G, Soos P, Mandera S, Heger U, Flechtenmacher C, Bahrle S, Seres L, Cziraki A, Gries A, Zsengeller Z, Vahl CF, Hagl S and Szabo C: INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock 21: 426-432, 2004.
25. Szabo C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R, Chen M, Mabley JG and Kollai M: Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 10: 28-35, 2004.
26. Bai P, Mabley JG, Liaudet L, Virag L, Szabo C and Pacher P: Matrix metalloproteinase activation is an early event in doxorubicin- induced cardiotoxicity. Oncol Rep 11: 505-508, 2004.
27. Masutani M, Nakagama H and Sugimura T: Poly(ADPribosyl) ation in relation to cancer and autoimmune disease. Cell Mol Life Sci 62: 769-783, 2005. (Pubitemid 40655627)
28. Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez MI, Valenzuela MT, Ruiz de Almodovar JM, De Murcia G and Oliver FJ: PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386: 119-125, 2005.